PharmaSGP Holding SE
XETRA:PSG

Watchlist Manager
PharmaSGP Holding SE Logo
PharmaSGP Holding SE
XETRA:PSG
Watchlist
Price: 25.2 EUR
Market Cap: 302.2m EUR
Have any thoughts about
PharmaSGP Holding SE?
Write Note

PharmaSGP Holding SE
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PharmaSGP Holding SE
Cost of Revenue Peer Comparison

Comparables:
ATAI
BAYN
MRK
93M1
DMP

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
PharmaSGP Holding SE
XETRA:PSG
Cost of Revenue
-€9.5m
CAGR 3-Years
-15%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
ATAI Life Sciences NV
NASDAQ:ATAI
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Cost of Revenue
-€19.8B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
0%
Merck KGaA
XETRA:MRK
Cost of Revenue
-€8.7B
CAGR 3-Years
-7%
CAGR 5-Years
-9%
CAGR 10-Years
-11%
MPH Health Care AG
XETRA:93M1
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Cost of Revenue
-€403.8m
CAGR 3-Years
-8%
CAGR 5-Years
-7%
CAGR 10-Years
N/A

See Also

What is PharmaSGP Holding SE's Cost of Revenue?
Cost of Revenue
-9.5m EUR

Based on the financial report for Dec 31, 2023, PharmaSGP Holding SE's Cost of Revenue amounts to -9.5m EUR.

What is PharmaSGP Holding SE's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-8%

Over the last year, the Cost of Revenue growth was -5%. The average annual Cost of Revenue growth rates for PharmaSGP Holding SE have been -15% over the past three years , -8% over the past five years .

Back to Top